Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Swedbank AB

Swedbank AB lessened its stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 23.3% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 334,517 shares of the life sciences company's stock after selling 101,359 shares during the period. Swedbank AB owned about 0.21% of Illumina worth $44,702,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in the company. Versant Capital Management Inc boosted its stake in shares of Illumina by 153.7% in the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock valued at $32,000 after purchasing an additional 146 shares during the period. TD Private Client Wealth LLC raised its stake in Illumina by 58.5% in the third quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company's stock valued at $50,000 after buying an additional 141 shares in the last quarter. Massmutual Trust Co. FSB ADV lifted its stake in Illumina by 65.1% during the third quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company's stock worth $56,000 after purchasing an additional 168 shares during the last quarter. Private Trust Co. NA boosted its holdings in shares of Illumina by 81.2% in the 3rd quarter. Private Trust Co. NA now owns 473 shares of the life sciences company's stock valued at $62,000 after buying an additional 212 shares in the last quarter. Finally, Focused Wealth Management Inc purchased a new stake in Illumina in the third quarter valued at $63,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Trading Up 1.3 %

Shares of NASDAQ:ILMN traded up $1.76 during trading on Thursday, reaching $133.48. The stock had a trading volume of 519,603 shares, compared to its average volume of 1,648,573. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94. The stock has a market cap of $21.17 billion, a P/E ratio of -13.34 and a beta of 1.11. The business has a fifty day moving average price of $139.05 and a 200-day moving average price of $135.05. Illumina, Inc. has a fifty-two week low of $100.08 and a fifty-two week high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, topping analysts' consensus estimates of $0.88 by $0.26. The company had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The business's revenue for the quarter was down 3.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.33 EPS. As a group, analysts anticipate that Illumina, Inc. will post 4.13 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ILMN has been the subject of a number of research analyst reports. Morgan Stanley decreased their target price on Illumina from $156.00 to $150.00 and set an "equal weight" rating for the company in a research report on Monday, January 13th. Citigroup cut shares of Illumina from a "buy" rating to a "neutral" rating and cut their target price for the company from $190.00 to $165.00 in a report on Wednesday, December 11th. HSBC raised shares of Illumina from a "hold" rating to a "buy" rating and set a $180.00 price objective on the stock in a research report on Thursday, October 17th. Canaccord Genuity Group increased their target price on shares of Illumina from $130.00 to $145.00 and gave the stock a "hold" rating in a research note on Tuesday, November 5th. Finally, Leerink Partners increased their price objective on Illumina from $160.00 to $200.00 and gave the stock an "outperform" rating in a research report on Thursday, October 17th. Eight analysts have rated the stock with a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $165.63.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.